*By Bridgette Webb*
Drugmaker Merck announced earlier this month it will slash prices on several drugs by 10 percent or more.
But there is a catch: the price rollback will only affect some of the smaller products in its portfolioーlike Hepatitis C drug, Zepatier, which accounts for about 4 percent of the company's salesーand not top sellers like cancer treatment Keytruda.
"Their scope is relatively limited," said Peter Loftus, a Reporter for the Wall Street Journal, during an interview on Cheddar Monday. "If you think about the total sales that Merck generatesーit's a relatively small percentage."
Merck's announcement was met with praise from the Trump administration. Health and Human Services Secretary Alex Azar claimed the drop in prices was spurred by Trump's latest crackdown on pharmaceutical companies.
Other big pharma names are following suit: Pfizer and Novartis announced they will freeze price increases for the rest of the year, earning them congratulatory tweets from the president.
Despite all of the price freezes and drops, Loftus says that patients may not actually see any real savings.
"I don't think you can say on a widespread basis, and really for the average drug or patient, that prices are coming down, there are still price increases."
For the full segment, [click here.]
(https://cheddar.com/videos/drugmakers-tout-lower-prices)
New research shows that exposure to polyfluoroalkyl substances (PFAS), also known as "forever chemicals" can hamper growth and development in children by "altering hormonal and metabolic pathways."
The Centers for Disease Control and Prevention (CDC) on Monday warned that a deadly fungus called Candida auris (C. auris) is spreading at an "alarming rate" in the U.S. healthcare facilities.
Karuna Therapeutics' top-experimental schizophrenia drug significantly reduced symptoms in a late-stage trial but there were concerns that it could cause hypertension in patients.
One of television's most successful writers made a big donation to the Cedars Sinai Medical Center in Los Angeles to help underserved community members gain the skills to become health care professionals.
The UN Intergovernmental Panel on Climate Change (IPCC) has released a new report providing multiple options for how the world can survive and adapt to climate change.
California Gov. Gavin Newsom over the weekend announced that the state has secured a contract with CIVCA to make $30 insulin available to all who need it. He also announced that the state will start manufacturing Naloxone, an emergency medication used to rapidly reverse the effects of an opioid overdose.
The global bottled water industry is booming, and it's coming at a steep environmental cost, according to the United Nations University Institute for Water, Environment and Health.
